It recommends healthcare practitioners should offer a low-dose combination of inhaled corticosteroids (ICS) and formoterol to be taken as needed for everyone aged 12 and over with newly diagnosed ...

These tools set cookies that store anonymised information about how you got to the site, and how you interact with the site.

According to the study, technologies that received scientific advice took a median of 312 days to progress from marketing ...

why there is a need for the guideline the areas the guideline will and will not cover what it intends to achieve. A draft scope is provided to organisations with an interest in the topic (known as ...

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

Join the NICE Board as a non-executive director and help shape the future of health and social care improvement. These cookies remember information that changes the way our website behaves or looks, ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Neupulse is a wearable wrist-worn device linked to a mobile phone app, used to treat those over the age of 12. The device delivers low-intensity electrical pulses to the median nerve to reduce tic ...

Are you facing challenges in quickly bringing new healthtech products to market? The NHS is a large and complex system and ...

Guidance that can help you make cost savings and find efficiencies in your local services. Includes impact reports and templates that allow you to accurately estimate savings for your local setting. A ...

The guideline aims to support healthcare professionals by providing them with information they need to support evidence-based decisions about treatment choices, as well as information and support ...

Just over 700 people in England are eligible to benefit from elranatamab for multiple myeloma that has returned and stopped responding to previous treatments, and who have had at least three lines of ...